Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PALI

Palisade Bio Inc

Dec 13 • 04:00PM ET

1.77

Dollar change -0.59
Percentage change -25.00	%

Healthcare • Biotechnology • USA • NASD

Peers: ONCT NRT ENTA LPTX GERN LVTX IMMP IKT HEPA

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-15.04	Insider Own	1.67%	Shs Outstand	1.43M	Perf Week	0.00%
Market Cap	2.52M	Forward P/E	-	EPS next Y	-3.81	Insider Trans	0.00%	Shs Float	1.40M	Perf Month	-19.55%
Income	-14.06M	PEG	-	EPS next Q	-2.24	Inst Own	4.36%	Short Float	7.68%	Perf Quarter	-54.96%
Sales	0.00M	P/S	-	EPS this Y	54.26%	Inst Trans	-	Short Ratio	0.09	Perf Half Y	-61.85%
Book/sh	5.51	P/B	0.32	EPS next Y	69.14%	ROA	-106.54%	Short Interest	0.11M	Perf Year	-79.93%
Cash/sh	5.65	P/C	0.31	EPS next 5Y	-	ROE	-135.96%	52W Range	1.38 - 22.35	Perf YTD	-80.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	75.28%	ROI	-212.85%	52W High	-92.08%	Beta	1.38
Dividend TTM	-	Quick Ratio	3.28	Sales past 5Y	-38.82%	Gross Margin	-	52W Low	28.26%	ATR (14)	0.41
Dividend Ex-Date	-	Current Ratio	3.28	EPS Y/Y TTM	65.70%	Oper. Margin	-	RSI (14)	40.66	Volatility	33.57% 17.33%
Employees	9	Debt/Eq	0.05	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	30.33
Option/Short	No / No	LT Debt/Eq	0.00	EPS Q/Q	68.50%	Payout	-	Rel Volume	1.62	Prev Close	2.36
Sales Surprise	-	EPS Surprise	30.80%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	1.17M	Price	1.77
SMA20	-18.45%	SMA50	-36.21%	SMA200	-58.60%	Trades		Volume	1,904,786	Change	-25.00%

Today 04:05PM	Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) -25.00%
Dec-12-24 12:05PM	Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules (GlobeNewswire) +68.57%
Dec-03-24 08:15AM	Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects (GlobeNewswire) -5.00%
Nov-21-24 08:15AM	Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) (GlobeNewswire)
Nov-14-24 09:00AM	Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit (GlobeNewswire) +19.09%
08:45AM	Loading…
Nov-12-24 08:45AM	Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 (GlobeNewswire)
Nov-07-24 08:30AM	Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) (GlobeNewswire)
Oct-31-24 08:30AM	Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -12.26%
Oct-15-24 08:00AM	Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-10-24 08:30AM	Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Oct-08-24 08:00AM	Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -7.10%
Sep-25-24 08:00AM	Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -9.66%
Sep-16-24 08:00AM	Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies (GlobeNewswire)
Sep-05-24 08:00AM	Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification (GlobeNewswire)
Aug-19-24 08:00AM	Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.38%
08:05AM	Loading…
Aug-13-24 08:05AM	Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-08-24 08:00AM	Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis (GlobeNewswire)
Jul-31-24 09:15AM	Palisade Bio Participates in Virtual Investor What this Means Segment (GlobeNewswire) +11.68%
Jul-29-24 08:30AM	Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108 (GlobeNewswire) -12.08%
Jul-19-24 08:30AM	Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jul-11-24 08:00AM	Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product (GlobeNewswire)
Jun-24-24 09:00AM	Palisade Bio to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire)
Jun-21-24 08:15AM	Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences (GlobeNewswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 09:55AM	Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now (Zacks)
Jun-11-24 08:30AM	Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108 (GlobeNewswire)
Jun-10-24 09:15AM	Palisade Bio to Present at the Virtual Investor Pitch Conference (GlobeNewswire)
08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
May-21-24 08:30AM	Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models (GlobeNewswire) -7.52%
May-14-24 08:05AM	Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
10:53PM	Loading…
May-13-24 10:53PM	PALI Stock Earnings: Palisade Bio Beats EPS for Q1 2024 (InvestorPlace) -7.30%
May-07-24 08:30AM	Palisade Bio Appoints Margery Fischbein to its Board of Directors (GlobeNewswire) -6.62%
07:30AM	Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules (GlobeNewswire)
May-02-24 08:30AM	Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules (GlobeNewswire)
May-01-24 08:30AM	Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) (GlobeNewswire) +17.41%
Apr-23-24 08:30AM	Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach (GlobeNewswire) +20.08%
Apr-16-24 11:22AM	Why Is Palisade Bio (PALI) Stock Up 57% Today? (InvestorPlace) +42.55%
08:30AM	Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool (GlobeNewswire)
Apr-11-24 09:15AM	Palisade Bio to Participate in the Virtual Investor Lunch Break Event (GlobeNewswire) +7.62%
Apr-10-24 08:15AM	Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis (GlobeNewswire) -24.91%
Apr-03-24 05:30PM	Palisade Bio Announces 1-for-15 Reverse Stock Split (GlobeNewswire)
Mar-27-24 08:00AM	Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +6.04%
Mar-26-24 11:52PM	PALI Stock Earnings: Palisade Bio Beats EPS for Q4 2023 (InvestorPlace)
Feb-15-24 08:35AM	Palisade Bio to Present at Digestive Disease Week (DDW) 2024 (GlobeNewswire)
Feb-13-24 08:35AM	Palisade Bio Provides Corporate Update and Reiterates Guidance (GlobeNewswire)
Feb-08-24 02:40PM	Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members (GlobeNewswire)
08:05AM	Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders (GlobeNewswire)
Jan-30-24 09:25AM	Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million (GlobeNewswire) -35.01%
Jan-29-24 02:01PM	Why Is Palisade Bio (PALI) Stock Up 100% Today? (InvestorPlace) +84.62%
08:05AM	Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress (GlobeNewswire)
Jan-09-24 08:00AM	Palisade Bio Selected for Poster Presentation at the 2024 Crohn's & Colitis Congress (GlobeNewswire)
Dec-29-23 04:52AM	Palisade Bio receives milestone payment for PALI-2108 development (Pharmaceutical Business Review) -9.77%
Dec-28-23 08:00AM	Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108 (GlobeNewswire) +8.98%
Nov-10-23 08:05AM	Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook (GlobeNewswire)
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE)
Oct-11-23 09:05AM	Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference (GlobeNewswire)
Sep-14-23 07:13PM	Insider Buying: John Finley Acquires 15,000 Shares of Palisade Bio Inc (GuruFocus.com)
Sep-11-23 04:01PM	Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules (GlobeNewswire) -5.48%
08:35AM	Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Sep-07-23 08:30AM	Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules (GlobeNewswire) -45.85%
Sep-06-23 08:45AM	Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease (GlobeNewswire) +108.79%
Aug-11-23 08:05AM	Palisade Bio Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 08:05AM	Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions (GlobeNewswire) -62.70%
Jul-05-23 08:45AM	Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study (GlobeNewswire)
Jun-22-23 08:30AM	PALISADES ANNOUNCES NEW FOUND MAKES NEW HIGH-GRADE, AT SURFACE DISCOVERY AT JACKPOT ZONE AT QUEENSWAY PROJECT (PR Newswire)
Jun-14-23 08:45AM	Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire)
Jun-01-23 08:45AM	Palisade Bio Promotes J.D. Finley to Chief Executive Officer (GlobeNewswire) +9.09%
May-24-23 08:45AM	Palisade Bios LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts (GlobeNewswire) -7.64%
May-17-23 08:30AM	PALISADES ANNOUNCES NEW FOUND GOLD INTERCEPTS AT KEATS WEST (PR Newswire)
May-12-23 08:05AM	Palisade Bio Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-11-23 09:05AM	Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study (GlobeNewswire)
Apr-06-23 09:00AM	Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148 (GlobeNewswire)
Apr-05-23 08:35AM	Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148 (GlobeNewswire) +7.39%
Apr-04-23 08:30AM	PALISADES ANNOUNCES NEW FOUND GOLD INTERCEPTS AT ICEBERG (PR Newswire) -10.18%
Apr-03-23 08:30AM	Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules (GlobeNewswire) -35.80%
Mar-23-23 08:05AM	Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-15-23 08:30AM	PALISADES ANNOUNCES NEW FOUND'S INCREASED WEIGHTING BY GDXJ (PR Newswire) -6.60%
Mar-01-23 09:05AM	Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent (GlobeNewswire)
Feb-08-23 08:35AM	Palisade Bio Promotes Robert McRae to Chief Operating Officer (GlobeNewswire)
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Jan-10-23 08:35AM	Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million (GlobeNewswire)
Jan-09-23 08:45AM	Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event (GlobeNewswire)
Jan-04-23 05:15PM	Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules (GlobeNewswire) +6.02% -20.00%
Dec-30-22 08:45AM	Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules (GlobeNewswire) +61.49%
Dec-16-22 08:05AM	Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions (GlobeNewswire)
Dec-07-22 08:35AM	Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million (GlobeNewswire) -6.81%
Dec-01-22 02:44PM	Palisade Bio Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Nov-22-22 08:35AM	Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery (GlobeNewswire) +81.90%
Nov-18-22 08:05AM	Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer (GlobeNewswire) -7.89%
Nov-17-22 08:30AM	Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video (GlobeNewswire) -5.67%
Nov-15-22 11:15AM	Palisade Bio Announces Reverse Stock Split (GlobeNewswire) -18.56%
Nov-14-22 08:45AM	Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-11-22 09:25AM	Palisade Bio Announces Executive Leadership Transition (GlobeNewswire) -12.78%
Sep-29-22 08:35AM	Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022 (GlobeNewswire) -6.28%
Sep-23-22 04:30PM	Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.61%
Sep-21-22 09:23AM	Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference (GlobeNewswire)
Sep-15-22 08:30AM	Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead Clinical Program, LB1148 (GlobeNewswire) -9.15%
Sep-13-22 09:05AM	Palisade Bio to Present at the Virtual Investor Innovations in Intestinal Health - Launching a Pivotal Phase 3 Study for Return of Postoperative Bowel Function Event (GlobeNewswire) +18.33%
Aug-17-22 08:35AM	Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function (GlobeNewswire) -21.41%
Aug-16-22 04:05PM	Palisade Bio Announces Closing of $13.8 Million Upsized Underwritten Public Offering and Full Exercise of Over-Allotment Option (GlobeNewswire) -10.99%

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams Donald Allen	Director	Nov 21 '24	Option Exercise	0.00	388	0	728	Nov 22 04:00 PM
Wei Binxian	Director	Nov 21 '24	Option Exercise	0.00	388	0	855	Nov 22 04:00 PM
Wei Binxian	Director	Jun 11 '24	Option Exercise	0.00	465	0	467	Jun 12 09:41 PM
Williams Donald Allen	Director	Jun 11 '24	Option Exercise	0.00	340	0	340	Jun 12 09:40 PM
Jones Mitchell Lawrence	Chief Medical Officer	May 28 '24	Option Exercise	0.00	4,290	0	4,313	May 30 07:44 PM
Finley John David	CEO, CFO, Director	May 28 '24	Option Exercise	0.00	7,068	0	14,079	May 30 07:44 PM
Williams Donald Allen	Director	May 28 '24	Buy	4.86	1,000	4,863	1,000	May 29 03:47 PM
Finley John David	CEO, CFO, Director	May 24 '24	Buy	4.81	1,000	4,810	8,437	May 28 06:02 AM
Jones Mitchell Lawrence	CEO, CFO, Director	May 06 '24	Option Exercise	0.00	460	0	880	May 08 06:37 PM
Finley John David	CEO, CFO, Director	May 06 '24	Option Exercise	0.00	443	0	6,832	May 08 06:36 PM
Finley John David	CEO, CFO, Director	Mar 11 '24	Option Exercise	0.00	5,558	0	96,849	Mar 12 06:29 PM
Neal James R	Director	Feb 09 '24	Option Exercise	0.00	10,920	0	10,920	Feb 13 03:08 PM
Csimma Cristina	Director	Feb 08 '24	Option Exercise	0.00	12,800	0	12,862	Feb 13 03:08 PM
Trenschel Robert J.	Director	Feb 08 '24	Option Exercise	0.00	10,920	0	10,920	Feb 13 03:08 PM
Diaz Stephanie	Director	Feb 08 '24	Option Exercise	0.00	12,800	0	12,800	Feb 13 03:08 PM
Jones Mitchell Lawrence	Chief Medical Officer	Feb 06 '24	Option Exercise	0.00	6,891	0	9,815	Feb 08 04:38 PM
Finley John David	CEO, CFO, Director	Feb 06 '24	Option Exercise	0.00	6,642	0	91,291	Feb 08 04:37 PM
Finley John David	CEO, CFO, Director	Feb 06 '24	Buy	0.47	10,000	4,692	84,649	Feb 07 08:30 AM
Finley John David	CEO, CFO, Director	Jan 31 '24	Buy	0.56	10,000	5,590	74,649	Feb 01 08:30 AM
Williams Donald Allen	Director	Jan 31 '24	Buy	0.60	10,000	6,050	30,000	Feb 01 08:30 AM
Finley John David	CEO, CFO, Director	Jan 03 '24	Option Exercise	0.00	1,309	0	64,649	Jan 05 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PALI

Palisade Bio Inc

Upgrade your FINVIZ experience